Hanmi accepts USD 80 million upfront payment for technology transfer from Genentech

On the 25^th of January, Hanmi Pharm made a notice that the company has accepted the USD 80 million upfront payment for the 2016’s technology transfer to Genentech and separate the amount into 30 months for the accounting purpose.

Hanmi Pharm singed a technology transfer agreement of the ‘HM95573’ technology – an oral targeted therapy which inhibits RAF, one of mitogen-activated protein kinases...